Cite
MLA Citation
Michael Yellin et al.. “406 CDX527–01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A247. http://access.bl.uk/ark:/81055/vdc_100144709889.0x000002